agenda

COVERING ALL THE IMPORTANT TOPICS

 
 

Amsterdam, 12 - 13 March 2024

Schedule

Create your personal agenda –check the favourite icon

Mar 128:55
Conference pass

Chair's remarks

Keynotes
Chris Mancill, Senior Vice President & Head, Worldwide Value Access, Payment and HEOR, Bristol Myers Squibb
Mar 129:00
Conference pass

Keynote presentation

Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, Janssen
Mar 129:40
Conference pass

Keynote presentation

Keynotes
Timothy Lenehan, Corporate Vice President, Head of Global Market Access, Novo Nordisk
Mar 1211:40
Conference pass

Chair's Remarks

Evidence
Igor Rudychev, Vice President, Enterprise Analytics, Horizon Therapeutics
Mar 1211:40
Conference pass

Chair's Remarks

Market Access
Laurene Redding, Global Head, Value, Access & Pricing, ex-China, BeiGene
Mar 1211:40
Conference pass

Chair's Remarks

Pricing
Astrid Buys, Director, Global Head of Tenders and Pricing, Bavarian Nordic A/S
Mar 1211:40
Conference pass

Chair's Remarks

Rare Diseases
Gina Ewy, VP, Head of Global Market Access, Hansa Biopharma
Mar 1211:40
Conference pass

Chair's Remarks

Advanced Therapies
Fabrizio Gianfrate, Full Professor, Health Economics and Outcomes Research, Former AIFA
Mar 1211:40
Conference pass

Chair's Remarks

Digital Transformation
Ivanna Rosendal, Senior Director, Head of Commercial and Medical IT, Ascendis Pharma A/S
Mar 1211:40
Conference pass

Chair's Remarks

HTA
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 1211:40
Conference pass

Chair's Remarks

Health Economics & Outcomes Research
Shrividya Iyer, Independent Expert, RWE and HEOR, Independent Expert
Mar 1211:45
Conference pass

Patient centred integrated evidence generation

Evidence
Agathe Le Lay, Vice President, Head of Global Value Evidence & Patient Insights, Medical Affairs, H. Lundbeck A/S
Mar 1211:45
Conference pass

Industries commitments to file across the EU 27

Market Access
Neil Mulcock, Vice President, International Government Affairs and Policy, Gilead Sciences
Mar 1211:45
Conference pass

European pricing and developments: future out-looks & rare diseases

Pricing
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Mar 1211:45
Conference pass

Orphan medicines regulation review – where are we now?

Rare Diseases
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Mar 1211:45
Conference pass

Early pipeline development for advanced therapies

Advanced Therapies
Kalitsa Filioussi, Global Director, Early Access, Novartis
Mar 1211:45
Conference pass

HTA for artificial intelligence: where are we now?

Digital Transformation
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management (ALTEMS)
Mar 1211:45
Conference pass

Minding the evidence gap: a day in a life of a HTA assessor

HTA
Zinajda Zolic-Karlsson, Senior advisor HTA, Norwegian Medicines Agency
Mar 1211:45
Conference pass

Clinical outcomes assessments in rare diseases and HEOR

Health Economics & Outcomes Research
Dilesh Doshi, Vice President, Global Health Economics and Outcomes Research, Acadia Pharmaceuticals Inc.
Mar 1212:25
Conference pass

Evidence for HTA: delivering the biggest impact

Evidence
Sandeep Kiri, Global Head, Health Economics and HTA Evidence, Ucb
Mar 1212:25
Conference pass

Opportunities and challenges in the evolving healthcare procurement environment

Market Access
Donal O'Sullivan, Vice President, Head of Pricing & Tenders, CSL Vifor
Mar 1212:25
Conference pass

Opportunities and challenges in the evolving healthcare procurement environment

Pricing
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Mar 1212:25
Conference pass

Driving solutions and understanding barriers for patient access in rare diseases

Rare Diseases
Stefaan Fiers, Head of Corporate Communication, Public Affairs & Patient Advocacy, Belgium, Takeda
Mar 1212:25
Conference pass

Patient access for advanced therapies

Advanced Therapies
Rita Shorjian, Commercial Director, Determatology, Intercontinental, Middle East, Africa and Russia, Abbvie
Mar 1212:25
Conference pass

Improving access to digital therapeutics in Europe

Digital Transformation
Tina Taube, Director, Market Access and Orphan Drug Policy Lead, EFPIA
Mar 1212:25
Conference pass

Framework and implementation for HTAR regulation

HTA
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Mar 1212:25
Conference pass

Innovating economic processes for improved patient access

Health Economics & Outcomes Research
Ariella Toren, Director, Medicine and Medical Technologies, HMOS Department, Ministry of Health, Israel
Mar 1214:05
Conference pass

01 Evidence Panel – Current HTA trends and impacts on evidence

Evidence
Sally Chung, Vice President, Head of Market Access & Pricing Europe, GSK
Diana Sinkevich, Head of Market Access, Europe & Emerging Markets, Chiesi
Shuvayu Sen, Vice President and Head of Oncology, Center of Observational & Real World Evidence, MERCK
Tanja Podkonjak, Director, Access and Reimbursement Policy, Oncology, EUCAN, Takeda
Enkeleida Nikai-Fitzgerald, Vice President, Head of Global Real-World Evidence, GenMed, Sanofi
Mar 1214:05
Conference pass

02 Market Access Panel – Title TBC

Market Access
Mata Charokopou, Senior Director, Global Head of Access, Pricing & Value, Ucb
Laurent Carter, Senior Vice President, Head of Global Pricing, Bristol-Myers Squibb
Julien Patris, Head of Patient Advocacy and Public Policy, EMEA, arGEN-X
Pernille Storm, Vice President, Global Pricing and Market Access, Lundbeck
Birgit Holz, Global Head, Contracting Innovation, Sanofi
Matt Cullen, Vice President, Value, Access & Policy, Apellis Pharmaceuticals
Mar 1214:05
Conference pass

04 Rare Diseases – Barriers and solutions to medicine access for patients with rare diseases

Rare Diseases
Lorenzo Capretto, Market Access Lead, Europe & Emerging Markets, Chiesi
Juliette Vila Sinclair/Spence, Rare Disease Patient Advocate & Chairwoman, Acanthamoeba Keratitis Eye Foundation
Christine Mossa, Senior Director, Regulatory Affairs, Public Affairs, Value & Access, Ipsen Biopharmaceuticals Canada Inc.
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Diseases & Rare Diseases International
Mar 1214:05
Conference pass

06 Digital Transformation - Integrating pharmaceuticals for digital health solutions: evidence for pricing and access

Digital Transformation
Jesper Bjerggren, Associate Director, European Market Access, Teva Pharmaceuticals
Mar 1214:05
Conference pass

08 Market Access Panel – Market access for advanced diagnostics and comprehensive genomic profiling

Health Economics & Outcomes Research
Benjamin Gannon, Vice President, International, Guardant Health
Mar 1215:10
Conference pass

Chair's Remarks

Market Access
Michael Mueller, Head Of Market Access, Western Europe, Sun pharma
Mar 1215:10
Conference pass

Chair's Remarks

Pricing
Tomaso Piaggio, Director, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Mar 1215:10
Conference pass

Chair's Remarks

Rare Diseases
Luigi Angelillo, Director, Market Access EMEA, Argenx
Mar 1215:10
Conference pass

Chair's Remarks

Advanced Therapies
Lisette Kaskens, Director, Market Access, Europe, LATAM & Canada, Ferring Pharmaceuticals
Mar 1215:10
Conference pass

Chair's Remarks

Digital Transformation
Igor Solev, Global Head of Market Access, Policy & External Payer Affairs, Abbott Laboratories
Mar 1215:10
Conference pass

Chair's Remarks

HTA
Josep Maria Guiu Segura, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Mar 1215:10
Conference pass

Chair's Remarks

Health Economics & Outcomes Research
Rhys Williams, Vice President, Evidence Generation Strategy and Health Economics, Global Medical Affairs (ex-China), BeiGene
Mar 1215:15
Conference pass

Are we ready to reach the WHO’s goals for oncology?

Evidence
Rafael Souza, Director, Access Solutions & Pricing, New Markets, BeiGene
Mar 1215:15
Conference pass

Bridging early access schemes during negotiations

Market Access
Ad Antonisse, Director, Market Access & External Affairs, AstraZeneca
Mar 1215:15
Conference pass

Pricing updates for Spain: future challenges

Pricing
José Luis Sánchez Chorro, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Mar 1215:15
Conference pass

The patient journey of accessing new treatments

Rare Diseases
Robert Burley, Director, Care, Campaigns and Support, The Muscular Dystrophy U.K.
Mar 1215:15
Conference pass

Pricing approaches for gene therapies: future innovations

Advanced Therapies
Lara Pippo, Head Of Market Access & Government Affairs, Italy, CSL Behring
Mar 1215:15
Conference pass

How pharma can utilize patient level data for integrated business analytics

Digital Transformation
Teddy Sun, Evidence Generation Lead, Nordic Data Digital & Technology (DDT), Takeda
Mar 1215:15
Conference pass

Cost effectiveness thresholds and healthcare decision making: challenges for HTAs

HTA
Hans Severens, Independent HTA Expert, Former Vice President,, Dutch Health Council
Mar 1215:15
Conference pass

Outcomes research and real-world evidence for women’s health

Health Economics & Outcomes Research
Katja Lundell, Senior Director, Global Head of Pricing, Access and Communications, theramex
Mar 1215:35
Conference pass

Silver sponsor presentation - LCP

Market Access
Ad Antonisse, Director, Market Access & External Affairs, AstraZeneca
Mar 1215:55
Conference pass

Integrated evidence approaches: opportunities and challenges

Evidence
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Mar 1215:55
Conference pass

Driving solutions and understanding barriers for ac-cess to molecular diagnostics in LMICs

Market Access
Francesco Marinucci, Director, Global Market Access, Abbott
Mar 1215:55
Conference pass

Value based pricing for off-patent pharmaceuticals

Pricing
Kalman Emry Wijaya, Director, Head of Pricing, Tender and Contracting, Biogen
Mar 1215:55
Conference pass

Navigating implications of new legislation for orphan medicines: how patient voices can contribute

Rare Diseases
Helen Stoop, Senior Director, Head of Patient Advocacy, Europe & Canada, Takeda
Mar 1215:55
Conference pass

Managed entry agreements and solutions for access challenges in rare diseases and advanced therapies

Advanced Therapies
Charles Brown, Director, Global Pricing & Contracting, Novartis
Mar 1215:55
Conference pass

The HMOs in the era of drug competition: creating innovative solutions

Digital Transformation
Michal Davidescu, Health Access Specialist, Pfizer
Mar 1215:55
Conference pass

Impacts of EU HTA regulation on the German AMNOG

HTA
Friedhelm Leverkus, Director, HTA & Outcomes Research, Pfizer
Mar 1215:55
Conference pass

Modelling health inequalities in HEOR

Health Economics & Outcomes Research
Diar Fattah, Director, Health Economics and Outcomes Research, Vertex Pharmaceuticals
Mar 1216:45
Conference pass

Chair's Remarks

Evidence
Madhu Kabra, Global Director, Health Economics and Outcomes Research, MKGlobal
Mar 1216:45
Conference pass

Chair's Remarks

Market Access
Marie-Sharmila Blandino, Director, Global Access Strategy Lead, Amgen
Mar 1216:45
Conference pass

Chair's Remarks

Pricing
Penny Lovell, Head of Access, Pricing and External Engagement, Ucb
Mar 1216:45
Conference pass

Chair's Remarks

Rare Diseases
Thomas Hasmann, Head of Market Access, Europe, KalVista Pharmaceuticals
Mar 1216:45
Conference pass

Chair's Remarks

Advanced Therapies
Lorenzo Mantovani, Professor of Public Health, University Of Milano - Bicocca
Mar 1216:45
Conference pass

Chair's Remarks

HTA
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, National Evaluation Committee for Specialised Medicine, CZ
Mar 1216:45
Conference pass

Chair's Remarks

Health Economics & Outcomes Research
Ana Filipa Alexandre, Vice President, Head of Pricing and Market Access, Santen
Mar 1216:50
Conference pass

Balancing trade-offs to ensure broad patient access in infectious diseases

Evidence
Elizabeth Kinter, Vice President, Head of Evidence, Value and Access, Vir Biotechnology
Mar 1216:50
Conference pass

Novel payment models in oncology

Market Access
Alison Horsfield, Director, Global Access Strategy, AstraZeneca
Mar 1216:50
Conference pass

Pricing implications in the US on small biotechs: managing gross to net

Pricing
Jake McDowell, Vice President, Head of Market Access and Pricing, Partner Therapeutics
Mar 1216:50
Conference pass

Launching products for rare diseases: adjusting to international and local hurdles

Rare Diseases
Fabian Schmidt, Head of Market Access / HEOR, Recordati Rare Diseases Sarl
Mar 1216:50
Conference pass

Ensuring that academic innovations in advanced therapies reach patients

Advanced Therapies
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Mar 1216:50
Conference pass

Use of data for HTA: NICE’s digital journey

Digital Transformation
Shaun Rowark, Associate Director, Data Access and Analysis, NICE
Mar 1216:50
Conference pass

NHS and NICE processes for diagnostics

HTA
Shabana Malik, Director, Access, UK & Ireland, BIOMERIEUX
Mar 1216:50
Conference pass

Modelling novel and societal value elements for holistic value assessment in HTA

Health Economics & Outcomes Research
Ramiro Gilardino, Senior Director, Global HTA & Access Policy Lead, MSD
Mar 1217:30
Conference pass

Using real world evidence for support patient access

Evidence
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Mar 1217:30
Conference pass

Access to medicines in LMICs

Market Access
Annie Syntosi, Global Associate Director, Value & Access, HEOR, Global Health,, Novartis Pharma AG
Mar 1217:30
Conference pass

Finding common ground: collaborating between patients, payers and industry

Pricing
Nidhi Dani, Director, Global Market Access, Novartis
Mar 1217:30
Conference pass

Conditional reimbursement policies: moving forward with uncertain evidence

Rare Diseases
Paul Slobbe, Director, Access and External Affairs, Takeda Nederland B.V.
Mar 1217:30
Conference pass

What have we learned and the future outlook for risk sharing agreements for ATMPs

Advanced Therapies
Farzana Malik, Independent Market Access Expert
Mar 1217:30
Conference pass

Digital disruption demystified: practical approached to digital transformation in access

Digital Transformation
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Mar 1217:30
Conference pass

Implementing risk sharing agreements

HTA
Kärt Veliste, Service Manager, Department of Medicines and Medical Devices, Tervisekassa Estonian Health Insurance Fund
Mar 1217:30
Conference pass

Innovation in anti-infectives valuations

Health Economics & Outcomes Research
Amer Al-Taie, Senior Director, Value & Evidence Team Lead, Pfizer

Create your personal agenda –check the favourite icon

Mar 138:55
Conference pass

Chair's Remarks

Keynotes
Marco Rauland, Vice President, Global Head of GVAP Strategic Planning & Data Science, Global Evidence Demonstration, Market Access and Pricing, Merck Group
Mar 139:00
Conference pass

Keynote presentation

Keynotes
Charles Makin, Global Head, Health Economics and Outcomes Research, HTA & Real-World Evidence, Biogen
Mar 139:20
Conference pass

Trends for affordable access: reducing disparities in global inequity

Keynotes
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Mar 1310:00
Conference pass

Panel discussion – Ways that AI can transform pharma market access

Keynotes
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Sandro Cesaro, Head of Europe Market Access & Pricing, AstraZeneca
Alexander Bastian, Vice President, Value & Market Access, A.M. Pharma
Rogerio Ribeiro, Senior Vice President, Head of Global Commercial, Vaccines Business Unit, Takeda
Chris Mancill, Senior Vice President & Head, Worldwide Value Access, Payment and HEOR, Bristol Myers Squibb
Marco Rauland, Vice President, Global Head of GVAP Strategic Planning & Data Science, Global Evidence Demonstration, Market Access and Pricing, Merck Group
Mar 1311:40
Conference pass

Chair's Remarks

Evidence
Jonathan Plumb, Vice President, Head, Global Value & Access, Ferring Pharmaceuticals SA
Mar 1311:40
Conference pass

Chair's Remarks

Market Access
Eric Noehrenberg, Global Vice President, Market Access and Government Affairs, CORCYM
Mar 1311:40
Conference pass

Chair's Remarks

Pricing
Eduardo Santos, Executive Director, Therapeutic Area Head, General Medicines, Global Value, Access & Pricing, Amgen
Mar 1311:40
Conference pass

Chair's Remarks

Rare Diseases
Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda
Mar 1311:40
Conference pass

Chair's Remarks

Advanced Therapies
Ishita Gaikwad, Director, Global Integrated Access Strategy, Amgen
Mar 1311:40
Conference pass

Chair's Remarks

HTA
Alina Charter, VP Market Access, Pricing and Policy, Alnylam
Mar 1311:40
Conference pass

Chair's Remarks

Health Economics & Outcomes Research
Riad Dirani, Vice President, Global HEOR, Medical Operations & Excellence, Teva Pharmaceuticals
Mar 1311:45
Conference pass

Evidence generation for innovative therapies in mental health

Evidence
Lucinda Orsini, Vice President, Value and Outcomes Research, COMPASS Pathways
Mar 1311:45
Conference pass

Investment strategies in market access viability: policies in reimbursement

Market Access
Erin Mistry, Executive Vice President, Chief Commercial Officer, CorMedix Inc
Mar 1311:45
Conference pass

Value based healthcare: what’s next for the innovative value space?

Pricing
Chris Bidad, Global Head, Access Strategy and Payer Policy, AstraZeneca
Mar 1311:45
Conference pass

Delivering on value-based therapies for rare diseases in Canada

Rare Diseases
Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Diseases & Rare Diseases International
Mar 1311:45
Conference pass

Gaining a commercial presence in Europe with advanced diagnostics

Advanced Therapies
Benjamin Eckert, Senior Vice President, Market Access, Adaptive Biotechnologies
Mar 1311:45
Conference pass

Data assets and AI platforms: multi-modal approaches across the evidence spectrum

Digital Transformation
Sean McElligott, Executive Director, Head, US Health Economics Outcomes Research, Novartis
Mar 1311:45
Conference pass

Value proposition of innovations: complexities for HTAs

HTA
Michele de Guise, President and Chief Executive Officer, INESSS
Mar 1311:45
Conference pass

HEOR and access strategy: changing environments and broadening the definition of value

Health Economics & Outcomes Research
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Mar 1312:25
Conference pass

Evidence generation for policy development: alleviating health disparities

Evidence
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Janssen
Mar 1312:25
Conference pass

Innovative medicines platform: what does this mean for EU access policy?

Market Access
Matt Slabbert, Vice President, Global Head of Pharma Public Affairs, Bayer
Mar 1312:25
Conference pass

Pricing from a start-up perspective

Pricing
Keith White, Head, Global Market Access, Amylyx Pharmaceuticals
Mar 1312:25
Conference pass

Engagements with payers for a product in an ultra-rare disease

Rare Diseases
Luca Tofani, Director, Pricing and Reimbursement, S.I.F.I. Spa
Mar 1312:25
Conference pass

Pricing and reimbursement mechanisms for advanced therapeutic medicinal products in 20 countries

Advanced Therapies
Juan Carlos Rejon-Parrilla, Senior HTA and Health Policy Researcher, Andalusian Regional Department of Health
Mar 1312:25
Conference pass

Supporting the NHS in digital transformation: partnerships for innovation

Digital Transformation
Sarah Ferry, Senior Policy Advisor, Innovation & Life Sciences, NHS Confederation
Mar 1312:25
Conference pass

Equity of access: developing ethical standards

HTA
Lorenzo Montrasio, Senior Scientific Officer, Council of Europe
Mar 1312:25
Conference pass

When is the ideal moment to start your HEOR activities within product development?

Health Economics & Outcomes Research
Kun Shi-van Wielink, EMEA Associate Director, HEOR/RWE Market Access, Santen
Mar 1314:05
Conference pass

01 Evidence Panel – Designing clinical development programmes: optimizing evidence generation for market access

Evidence
Adrian Harrington, Senior Director, Value & Access, Biogen
Elisa Crovato, Director, Pricing & Market Access, Chiesi Group
Steve Sandor, Vice President, Market Access, Government Affairs and Trade, Paratek Pharmaceuticals , Inc.
Mar 1314:05
Conference pass

03 Pricing Panel – Tiered pricing for varied markets: is it of value to patient access?

Pricing
Seema Sondhi, Vice President, Head of Global Strategic Projects, Takeda
Bart Van Den Daele, Director, Market Access, Head of External Affairs, Gilead Sciences
Dierk Neugebauer, Vice President, Market Access, Bristol Myers Squibb
Alexander Roediger, Associate Vice President, Global Lead, Oncology Policy, MSD
Peter Sajosi, Director, Regional Value and Access Lead, Amgen
Nick Besseling, Manager, Value Strategies & Agreements, AstraZeneca
Mar 1314:05
Conference pass

04 Rare Diseases – Playing nicely in the same sandbox: working together for patient access

Rare Diseases
Tal Morginstin, Director, HTA division, Ministry of Health, Israel
Mary Lynne Van Poelgeest-Pomfret, President, World Federation For Incontinent Patients
Dawn Ireland, President & Founder, CDH International
Kim Stephens, Executive Director, Muenzer MPS Research & Treatment Center
Diego Ardigò, Global Rare Disease, Research & Development Head & Executive Board Member and Vice Chair, Chiesi Group & EUCOPE
Josie Godfrey, Co-Chief Executive Officer, Realise Advocacy
Mar 1314:05
Conference pass

05 Advanced Therapies Panel – Access to gene therapies: challenges, opportunities and learnings

Advanced Therapies
Sheena Thakkar, Director, Value & Evidence, Pfizer
Andrew Olaye, Executive Director, Head of Market Access and Partnership EMEA, Orchard Therapeutics Ltd
Gunter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies
Mar 1314:05
Conference pass

06 Digital Transformation Panel – Empowering patients to collect their outcomes: making value-based healthcare a reality

Digital Transformation
Jolanda Koenders, Head of New Product Planning, Central Southeast Europe, Takeda
Mar 1314:05
Conference pass

07 HTA Panel - Stakeholders' views on the implementation of the EU Health Technology Assessment (HTA)

HTA
Thomas Grub, Senior Expert, Global Pricing and Market Access, medac GmbH
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Diogo Teixeira Pereira, Affiliate Member of NOVA SBE, Health Economics & Management Knowledge Center, Universidade NOVA de Lisboa
Marco Penske, Head, Market Access & Healthcare Affairs, Germany, Boehringer-Ingelheim
Mar 1314:05
Conference pass

08 Health Economics & Outcomes Research Panel - Title TBC

Health Economics & Outcomes Research
Michael Schlander, Head of Division of Health Economics & Professor of Health Economics, German Cancer Research Center & University of Heidelberg
Ayman Semaan, Market Access & Pricing Lead, Biologix
Matthias Bischof, Senior Director, Global Health Economics, Novartis Gene Therapies
Marlene Gyldmark, Vice President, Global Head, HEOR & Epidemiology, Idorsia Pharmaceuticals
Mar 1315:10
Conference pass

Chair's Remarks

Evidence
Kaan Tunceli, Vice President and Head, Global Value and Real World Evidence, Otsuka Pharmaceutical
Mar 1315:10
Conference pass

Chair's Remarks

Market Access
Allister Upton, Director, Market Access and Business Development, EMEA, Alimera Sciences Ltd
Mar 1315:10
Conference pass

Chair's Remarks

Pricing
Sebastian Kessel, Senior Director, Head of Market Access & External Engagement Germany, UCB
Mar 1315:10
Conference pass

Chair's Remarks

Rare Diseases
Marcus Dahlman, Head of Market Access Europe, Hansa Biopharma
Mar 1315:10
Conference pass

Chair's Remarks

Health Economics & Outcomes Research
Carme Pinyol, Early Products and HEOR Lead, Novartis
Mar 1315:15
Conference pass

Generating evidence for launches: creating innovative approaches

Evidence
Rachel Studer, Global Executive Director Launch Evidence, Novartis
Mar 1315:15
Conference pass

Reimbursement and pricing impacts on products in Israel

Market Access
Tomer Ben Zaken, Director, Head of Sick Funds & Hospitals Access, Abbvie
Mar 1315:15
Conference pass

Pricing challenges for plasma derived therapies (PDTs): value-based pricing and procurement practices

Pricing
Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT, Takeda
Mar 1315:15
Conference pass

Market access with patient advocacy organisations: best practices and challenges

Rare Diseases
Kirsty Hoyle, Chief Executive Officer, Metabolic Support UK
Mar 1315:15
Conference pass

Defining value in advanced therapies: the case of hemophilia

Advanced Therapies
Paolo Angelo Cortesi, Assistant Professor in Public Health, Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.
Mar 1315:15
Conference pass

Transforming discussions into understanding

Digital Transformation
Par Bolina, Adjunct Associate Professor, Medicinal Chemistry, Rutgers University
Mar 1315:15
Conference pass

Bridging of evidence to appraisals: aligning policy decisions

HTA
Goedele van Haasteren, Deputy chief Section HTA, Federal Office of Public Health, Switzerland
Mar 1315:15
Conference pass

The impact of austerity on healthcare: is cost containment the way forward?

Health Economics & Outcomes Research
Christina Vandorou, Director, Macroeconomics And Health Policy, EMEA, Janssen
Mar 1315:55
Conference pass

Fit for purpose evidence generation to advance mental health

Evidence
Marianne Laouri, Executive Director, Value Demonstration, Specialty Products & Quality of Care, Boehringer Ingelheim
Mar 1315:55
Conference pass

Market access for digital health assets: creating frameworks for digital health technologies

Market Access
Bogdan Muresan, Director, Global HEOR, Astellas Pharma
Mar 1315:55
Conference pass

Pricing and contracting: not one size fits all

Pricing
Claudia Neuber, Head of Global Pricing, Oncology, AstraZeneca
Mar 1315:55
Conference pass

Increasing generic competition for rare diseases & patient convenience

Rare Diseases
Bjørn Bayer, Director, Therapeutic Area CVMRPH, Janssen
Mar 1315:55
Conference pass

Prelaunch build up in US and Eu-rope for pricing and reimbursement in advanced therapies

Advanced Therapies
Dilip Patel, VP Market Access, Autolus
Mar 1315:55
Conference pass

Emerging digital health access in Asia Pacific

Digital Transformation
Anh Bourcet, External Advisor, Market Access Lead, APACMed, Asia Pacific Medical Technology Association
Mar 1315:55
Conference pass

HTA and price negotiations – experiences and expectations for the future

HTA
Erik Sagdahl, Head of Procurement, Pharmaceutical Division, Sykehusinnkjop
Mar 1315:55
Conference pass

Exploring patient registries for access: managing market access with real world evidence

Health Economics & Outcomes Research
Patricia Dorling, Head, Global HEOR and Real World Evidence, Chiesi Group
Mar 1316:45
Conference pass

Chair's Remarks

Pricing
Marina Faiella, Director, Forecasting and Business Analytics, BeiGene
Mar 1316:45
Conference pass

Chair's Remarks

Rare Diseases
Simon Shohet, Vice President, Market Access, International, Amicus Therapeutics
Mar 1316:50
Conference pass

Creating a tool to assess obesity’s impact on a patient’s daily life

Evidence
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Mar 1316:50
Conference pass

Broadening the definition of value: comprehensive stakeholder perspectives

Market Access
Lori Yin, Associate Director, Access Lead, Roche
Mar 1316:50
Conference pass

Recent developments in pricing and commercial access frameworks in England

Pricing
Rob Kettell, Director, Commercial Medicines Negotiation and Complex Transactions, NHS England
Mar 1316:50
Conference pass

Evidence generation in rare disease development programs

Rare Diseases
Giorgio Iotti, Head Of Program Leadership And Control, Rare Disease Unit, Chiesi Farmaceutici SpA
Mar 1316:50
Conference pass

Transition of a hospital set ATMP into an outpatient setting

Advanced Therapies
Andre Roeder, Head, Global Market Access, TETEC AG
Mar 1316:50
Conference pass

Creating virtual clinics for long covid: lessons learned from innovative digital health

Digital Transformation
Daniella Rahamim-Cohen, Director, Community Medicine, Maccabi Healthcare Services
Mar 1316:50
Conference pass

How new access schemes including risk management can contribute to coverage decisions in Latin America

HTA
Andres Pichon Riviere, Executive Director, Health Technology Assessment And Economic Evaluations, I.E.C.S.
Mar 1316:50
Conference pass

Addressing health inequities: bridging the gap

Health Economics & Outcomes Research
Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, BeiGene
Mar 1317:30
Conference pass

A network of secure data environments: enabling health technology assessments

Evidence
Rebecca Cosgriff, Head of Data for R&D, NHS England
Mar 1317:30
Conference pass

Deconstructing value based pricing: an economist’s perspective

Pricing
Jörg Mahlich, Market Access and Government Affairs Lead, Miltenyi
Mar 1317:30
Conference pass

Alternative pricing structures for orphan medical products

Rare Diseases
Matthew Hanchard, Research Associate, University of Sheffield
last published: 19/Sep/23 14:55 GMT
 
 

Get Involved 
 

Sponsorship & Exhibition Sales


David Boore 
david.boore@terrapinn.com
+44 20 8164 3052

Conference Production


George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940

Marketing Opportunities


Diana Cobzac
diana.cobzac@terrapinn.com